TYRA241220C30000
- 3.15
- 0.000.00%
TYRA BIOSCIENCES, INC. Newsroom
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate
Tyra Biosciences to Present at Upcoming Investor Conferences
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $29
Tyra Biosciences Analyst Ratings
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30
Express News | Tyra Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $30 From $32
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $33
Tyra Biosciences GAAP EPS of -$0.41 Beats by $0.06
Express News | Tyra Biosciences Inc Q3 Shr View $-0.40 -- LSEG IBES Data
TYRA BIOSCIENCES, INC. | 10-Q: Q3 2024 Earnings Report
TYRA BIOSCIENCES, INC. | 8-K: Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Express News | Tyra Biosciences Q3 Net Income USD -24.016 Million
Press Release: Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $32
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Tyra Bioscience Cleared by FDA to Conduct Phase 2 Study in Pediatric Achondroplasia
Express News | Tyra Biosciences Inc - First Child With Achondroplasia Expected to Be Dosed in Q1 2025
Express News | Tyra Biosciences Receives Ind Clearance From FDA to Proceed With Phase 2 Study of Tyra-300 in Pediatric Achondroplasia (Beach301)
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $32